BetterLife Pharma Inc.
BetterLife Pharma Inc.

BetterLife Pharma Inc. ("BetterLife") is an emerging biotechnology company primarily focused on developing and commercializing two compounds, TD-0148A and TD-010, to treat neurological disorders such as depression, cluster headaches and anxiety. TD-0148A is a non-hallucinogenic and non-controlled psychedelic candidate and is unique in that it is not regulated and therefore can be self-administered. TD-010 is a treatment of anxiety without the addictive potential of benzodiazepines. BetterLife also owns a drug candidate for the treatment of viral infections such as COVID-19 and is in the process of seeking strategic alternatives for further development.
BetterLife Pharma Inc. (BETR)
SEDAR Information
Company Info
Capitalization
Bulletins
2020-0836 – Fundamental Change - BetterLife Pharma Inc. (BETR)
Le 31 aout/August 2020
Following a fundamental change review the common shares of BetterLife Pharma Inc. have requalified for listing.
Listing and disclosure documents will be available at www.thecse.com on the trading date.
Advertisement
Publicité